February 14, 2022
Eisai said on February 10 that the company has submitted formal comments to the US Centers for Medicare and Medicaid Services (CMS), opposing its “overly restrictive” draft coverage proposal for amyloid-targeting antibodies for Alzheimer’s disease. On January 11, the CMS...read more